Bionano Genomics

BNGO

Market cap $13.1M

SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2026 and to highlight recent corporate progress.

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can significantly outperform traditional analytical methods for detection of structural variations and chromosomal abnormalities in multiple myeloma (MM), a complex hematologic malignancy known for its low success rate when analyzed by traditional cytogenetic methods. The multicenter study, led by scientists from Johns Hopkins University School of Medicine and The University of Texas MD Anderson Cancer Center, found that OGM performed on real-world clinical research samples was concordant with traditional methods, had a higher overall success rate for finding pathogenic or likely pathogenic abnormalities, and yielded a result for a substantial fraction of samples that failed to reveal an answer using traditional workflows, overcoming limitations of MM analysis by techniques such as fluorescence in situ hybridization (FISH), karyotyping, and next-generation sequencing (NGS).

Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript

Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday's regular session.

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano.

Bionano Genomics, Inc. (NASDAQ: BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress.

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics and molecular pathology by enabling digital karyotype construction.

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how these conditions, which include developmental delay, intellectual disability, neuromuscular disorders, reproductive disorders, birth defects and other so-called rare diseases, present unique challenges to the cytogenetics and molecular pathology teams investigating them. Unlike hematologic malignancies, where established guidelines may better define the search for relevant chromosomal aberrations and genetic variants, the genetic drivers of constitutional disorders are more typically unknown, which makes Bionano's end-to-end workflow based on the unbiased, genome-wide approach of optical genome mapping (OGM) particularly useful. Attendance at Symposium 2026 has grown to more than 1,200 participants from over 73 countries, with Day 3's presentations coming from Japan, India, Brazil, the Netherlands, Turkey, and the United States, while the online poster hall now features 50 posters.

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and Bioprocessing Applications with Optical Genome Mapping (OGM). The session revealed how OGM can offer a new standard for detecting and characterizing structural variants (SVs) across cancer, including its unprecedented resolution in rare and heterogeneous cancers.